• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Experience With the Priority Review Voucher Program for Drug Development.

作者信息

Kesselheim Aaron S, Maggs Lara R, Sarpatwari Ameet

机构信息

Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Harvard Medical School, Boston, Massachusetts.

出版信息

JAMA. 2015 Oct 27;314(16):1687-8. doi: 10.1001/jama.2015.11845.

DOI:10.1001/jama.2015.11845
PMID:26414802
Abstract
摘要

相似文献

1
Experience With the Priority Review Voucher Program for Drug Development.药物开发优先审评券计划的经验
JAMA. 2015 Oct 27;314(16):1687-8. doi: 10.1001/jama.2015.11845.
2
Efficacy of the Priority Review Voucher Program.优先审评券计划的成效。
JAMA. 2016 Apr 19;315(15):1659-60. doi: 10.1001/jama.2016.0377.
3
Efficacy of the Priority Review Voucher Program.优先审评券计划的成效
JAMA. 2016 Apr 19;315(15):1660-1. doi: 10.1001/jama.2016.0386.
4
US incentive scheme for neglected diseases: a good idea gone wrong?美国针对被忽视疾病的激励计划：一个出了差错的好主意？
BMJ. 2014 Jul 21;349:g4665. doi: 10.1136/bmj.g4665.
5
"Creating hope" and other incentives for drug development for children.为儿童开发药物的“创造希望”和其他激励措施。
Sci Transl Med. 2011 Jan 19;3(66):66cm1. doi: 10.1126/scitranslmed.3001707.
6
FDA launches priority vouchers for neglected-disease drugs.美国食品药品监督管理局推出针对被忽视疾病药物的优先券。
Nat Biotechnol. 2008 Dec;26(12):1315-6. doi: 10.1038/nbt1208-1315.
7
Priorities for the Priority Review Voucher.优先审评券的优先事项。
Am J Trop Med Hyg. 2017 Jan 11;96(1):14-15. doi: 10.4269/ajtmh.16-0600. Epub 2016 Aug 29.
8
The Commercial Market For Priority Review Vouchers.优先审评券的商业市场。
Health Aff (Millwood). 2016 May 1;35(5):776-83. doi: 10.1377/hlthaff.2015.1314.
9
Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases.引言：引入欧洲优先审评券制度以鼓励开发治疗被忽视疾病的新药。
Lancet. 2010 Sep 11;376(9744):922-7. doi: 10.1016/S0140-6736(10)60669-1.
10
Developing drugs for developing countries.为发展中国家研发药物。
Health Aff (Millwood). 2006 Mar-Apr;25(2):313-24. doi: 10.1377/hlthaff.25.2.313.

引用本文的文献

1
Progress, impacts and lessons from market shaping in the past decade: a systematic review.过去十年市场塑造的进展、影响及经验教训：一项系统综述
Front Public Health. 2025 Aug 21;13:1614471. doi: 10.3389/fpubh.2025.1614471. eCollection 2025.
2
Cross-sectional Study and Comparison between Japan and the United States on Special Regulatory Pathways for Expedited Drug Development and Approval.日本与美国在加速药物研发和审批特殊监管途径方面的横断面研究与比较。
Ther Innov Regul Sci. 2025 Apr 8. doi: 10.1007/s43441-025-00771-5.
3
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy.
药物研发的特殊 FDA 认定：孤儿药、快速通道、加速批准、优先审评和突破性疗法。
Eur J Health Econ. 2024 Aug;25(6):979-997. doi: 10.1007/s10198-023-01639-x. Epub 2023 Nov 14.
4
Changing incentives to ACCELERATE drug development for paediatric cancer.改变激励机制以加速儿科癌症药物研发。
Cancer Med. 2023 Apr;12(7):8825-8837. doi: 10.1002/cam4.5627. Epub 2023 Jan 16.
5
An Unnecessary Gift for COVID-19 Vaccines and Therapeutics: The Medical Countermeasure Priority Review Voucher.给新冠疫苗和治疗药物的一份不必要的礼物：医疗对策优先审评券
Am J Public Health. 2021 Nov;111(11):1923-1926. doi: 10.2105/AJPH.2021.306495. Epub 2021 Oct 14.
6
Antiparasitic Drugs in the United States-Two Roads to High Prices.美国的抗寄生虫药物——通往高价的两条途径。
Front Sociol. 2020 Oct 22;5:540478. doi: 10.3389/fsoc.2020.540478. eCollection 2020.
7
Access to benznidazole for Chagas disease in the United States-Cautious optimism?在美国，治疗恰加斯病的苯硝唑可及性——谨慎的乐观态度？
PLoS Negl Trop Dis. 2017 Sep 14;11(9):e0005794. doi: 10.1371/journal.pntd.0005794. eCollection 2017 Sep.
8
Association of the Priority Review Voucher With Neglected Tropical Disease Drug and Vaccine Development.优先审评券与被忽视热带病药物及疫苗研发的关联。
JAMA. 2017 Jul 25;318(4):388-389. doi: 10.1001/jama.2017.7467.
9
Research for new drugs for elimination of onchocerciasis in Africa.非洲治疗盘尾丝虫病新药的研究。
Int J Parasitol Drugs Drug Resist. 2016 Dec;6(3):272-286. doi: 10.1016/j.ijpddr.2016.04.002. Epub 2016 May 19.
10
Antileishmanial Activity of Ezetimibe: Inhibition of Sterol Biosynthesis, In Vitro Synergy with Azoles, and Efficacy in Experimental Cutaneous Leishmaniasis.依折麦布的抗利什曼原虫活性：对甾醇生物合成的抑制、与唑类药物的体外协同作用以及在实验性皮肤利什曼病中的疗效。
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6844-6852. doi: 10.1128/AAC.01545-16. Print 2016 Nov.